23.06.2017 | Marko D Banovic, Biomarkers in Medicine, 2017

Biomarkers in Medicine Ahead of Print.

mehr

23.06.2017 | Donna A Messner; Pei Koay; Jennifer Al Naber; Robert Cook-Deegan; Mary Majumder; Gail Javitt; Rachel Dvoskin; Juli B ..., Personalized Medicine, 2017

Aim: Identify solutions to the most important policy barriers to the clinical adoption of next-generation sequencing. Materials & methods: Four-round modified policy Delphi with a multistakeholder panel of 48 experts. The panel deliberated policy solutions to (previously reported) challenges ...

mehr

23.06.2017 | Elmar Nimmesgern; Irene Norstedt; Ruxandra Draghia-Akli, Personalized Medicine, 2017

Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment and care. It helps to address the challenge of the aging of the population, an increase in chronic disease and increasing healthcare costs. The EU is developing policies to move toward PM. This is underpinned ...

mehr

23.06.2017 | Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; C ..., Biomarkers in Medicine, 2017

Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other ...

mehr

23.06.2017 | Daniel B McArtor; Bochao D Lin; Jouke-Jan Hottenga; Dorret I Boomsma; Gonneke Willemsen; Gitta H Lubke, Biomarkers in Medicine, 2017

Aim: To assess the extent to which a multivariate approach to modeling interrelated hematological indices provides more informative results than the traditional approach of modeling each index separately. Materials & methods: The effects of demographics and lifestyle on ten hematological indices ...

mehr

22.06.2017 | Nahal Maroofi; Azita Azarkeivan; Soosan Banihashemi; Saeid Mohammadparast; Ali Aghajanirefah; Mehdi Banan, Pharmacogenomics, 2017

Aim: To identify the BCL11A intron-2 enhancer linkage disequilibrium (LD) block, harboring two previously identified SNPs, associating with the hydroxyurea response in β-thalassemia patients and the functional significance of this region. Materials & methods: Several neighboring SNPs were ...

mehr

22.06.2017 | Aizati N A Daud; Jorieke E H Bergman; Wilhelmina S Kerstjens-Frederikse; Pieter van der Vlies; Eelko Hak; Rolf M F B ..., Pharmacogenomics, 2017

Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in ...

mehr

22.06.2017 | Eva J Brandl; Henrik Walter, Pharmacogenomics, 2017

Pharmacogenomics Ahead of Print.

mehr

22.06.2017 | Frank Eektimmerman; Jesse J Swen; Stefan Böhringer; Tom WJ Huizinga; Wouter M Kooloos; Cornelia F Allaart; Henk-Jan ..., Pharmacogenomics, 2017

Aim: About 30% of rheumatoid arthritis patients have no clinical benefit from TNF inhibitors. Genome-wide association (GWA) and candidate gene studies tested several putative genetic variants for TNF inhibitor efficacy with inconclusive results. Therefore, this study applied a systematic pathway ...

mehr

22.06.2017 | Steven D Shapiro, Personalized Medicine, 2017

Personalized Medicine Ahead of Print.

mehr